CTIS2023-503822-38-00进行中（未招募）1 期
Randomized, open-label, single dose, two-period, cross-over bioequivalence study comparing test formulation Rosuvastatin/Amlodipine/Ramipril capsule, hard 10mg/5mg/5mg versus reference products Crestor 10 mg film coated tablets, Norvasc 5 mg tablets, Tritace 5 mg tablets in healthy male and female subjects under fasting conditions.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.not applicable (submitted trial is a bioequivalence in healthy subjects)MedDRA version: 20.0Level: HLGTClassification code: 10014523Term: Embolism and thrombosis Class: 10047065CTIS2024-513665-40-00Adamed Pharma S.A.62
Unknown
1 期
Open-label, randomized, single dose, two-period, two-treatment cross-over bioequivalence study of Dienogest 2 mg tablets from Naari Pharma Pvt. Ltd. - India vs Visanne 2 mg tablets, from Bayer Weimar GmbH UND Co.KG, Weimar, Germany in healthy female subjects under fasting conditionsHealthy subjectsBioequivalenceDienogest 2 mgTCTR20220906003Abbott Laboratories Limited, Thailand44
进行中（未招募）
1 期
Clinical trial in Healthy Volunteers to test Valsartan PharmacokineticsHypertensionEUCTR2016-004323-23-Outside-EU/EEAovartis86
已完成
1 期
A study to compare the concentrations of valsartan in plasma when valsartan is taken as solution formulation and as tablet formulation.CTRI/2010/091/001094ovartis Healthcare Private Limited Andhra Pradesh India30
尚未招募
不适用
Bioequialence study of two novel strengths of CoartemCTRI/2011/12/002256ovartis Healthcare Pvt Ltd120